An aqueous birch leaf extract of Betula pendula inhibits the growth and cell division of inflammatory lymphocytes

被引:22
作者
Gruendemann, Carsten [1 ]
Gruber, Christian W. [2 ]
Hertrampf, Anke [1 ]
Zehl, Martin [2 ]
Kopp, Brigitte [2 ]
Huber, Roman [1 ]
机构
[1] Univ Med Ctr Freiburg, Dept Environm Hlth Sci, Ctr Complementary Med, D-79106 Freiburg, Germany
[2] Univ Vienna, Dept Pharmacognosy, A-1090 Vienna, Austria
关键词
Betula pendula; Flavonoids; Arthritis; Lymphocytes; Apoptosis; Anthroposophic medicine; BLOOD MONONUCLEAR-CELLS; NF-KAPPA-B; RHEUMATOID-ARTHRITIS; MEDICINAL-PLANTS; QUERCETIN; DISEASE; EXPRESSION; APOPTOSIS; MECHANISMS; FLAVONOIDS;
D O I
10.1016/j.jep.2011.05.018
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Leaf extracts of Betula pendula have been traditionally used for the treatment of patients with rheumatoid arthritis (RA) or osteoarthritis. Aim of the study: We investigated the anti-proliferative capacity of an aqueous leaf extract of Betula pendula (BPE) on human primary lymphocytes in vitro, because activated lymphocytes play a major role in the initiation and maintenance of RA. Materials and methods: Lymphocyte proliferation and cell division was measured by the activity of mitochondrial dehydrogenases and by using the membrane-permeable dye carboxyfluorescein diacetate succinimidyl ester (CFSE), respectively. Apoptosis was analyzed by surface staining of phosphatidylserine and intracellular activation of effector caspases 3 and 7 in comparison to the drug methotrexate using flow cytometric and photometrical analysis. In addition, the impact of the extract on cell cycle distribution was investigated by propidium iodide staining of DNA. For the bioassays BPE concentrations of 10-160 mu g/mL were investigated. A phytochemical analysis, using LC-MS and HPLC, was conducted to identify the polyphenolic constituents of the birch leaf extract. Results: Leaf extracts of Betula pendula inhibited the growth and cell division (CD8(+): 40 mu g/mL: 45%; 80 mu g/mL: 60%; 160 mu g/mL: 87%) (CD4(+): 40 mu g/mL: 33%; 80 mu g/mL: 54%; 160 mu g/mL: 79%) of activated, but not of resting T lymphocytes in a significant dose-dependent manner. The inhibition of lymphocyte proliferation due to apoptosis induction (compared to untreated control: 40 mu g/mL: 163%; 80 mu g/mL: 240%; 160 mu g/mL: 348%) and cell cycle arrest was comparable to that of methotrexate. LC-MS analyses showed that the extract contains different quercetin-glycosides. Conclusion: Our results give a rational basis for the use of Betula pendula leaf extract for the treatment of immune disorders, like rheumatoid arthritis, by diminishing proliferating inflammatory lymphocytes. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:444 / 451
页数:8
相关论文
共 32 条
[1]   Cellular environments and apoptosis: Tissue microenvironments control activated T-cell death [J].
Akbar, AN ;
Salmon, M .
IMMUNOLOGY TODAY, 1997, 18 (02) :72-76
[2]   Increased expression of CD40 ligand (CD154) on CD4+T cells as a marker of disease activity in rheumatoid arthritis [J].
Berner, B ;
Wolf, G ;
Hummel, KM ;
Müller, GA ;
Reuss-Borst, MA .
ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (03) :190-195
[3]   Why does chronic inflammatory joint disease persist? [J].
Buckley, CD .
CLINICAL MEDICINE, 2003, 3 (04) :361-366
[4]   Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis. [J].
Choy, EHS ;
Panayi, GS .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) :907-916
[5]   Essential Oil of Betula pendula Roth. Buds [J].
Demirci, Betuel ;
Paper, Dietrich H. ;
Demirci, Fatih ;
Baser, K. Huesnue Can ;
Franz, Gerhard .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2004, 1 (03) :301-303
[6]  
*EP, 2011, EUR DIR QUAL MED S2, V2
[7]  
European Pharmacopoeia (EP), 2011, EUR DIR QUAL MED S1, V1
[8]  
*FED I DRUGS MED D, 2010, GERM HOM PHARM GHP S, V2
[9]  
*FED I DRUGS MED D, 2010, GERM HOM PHARM GHP S, V1
[10]   Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells [J].
Genestier, L ;
Paillot, R ;
Fournel, S ;
Ferraro, C ;
Miossec, P ;
Revillard, JP .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (02) :322-328